Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vanucizumab, a pioneering bispecific IgG1-like monoclonal antibody, concurrently inhibits the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their respective receptors, exerting antiangiogenic and anticancer properties [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Vanucizumab, a pioneering bispecific IgG1-like monoclonal antibody, concurrently inhibits the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their respective receptors, exerting antiangiogenic and anticancer properties [1]. |
Cas No. | 1448221-05-3 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.